Training Experience Required
- MD degree is compulsory.
- PhD degree is optional; however MSc degree is a plus.
- Willingness to learn French
Institut Curie dates back to 1909, when Marie Curie implemented in the heart of Paris her bench-to-bedside vision of a research-care continuum. A leading player in the fight against cancer, the internationally renowned Institut Curie combines a Research Center and a Hospital Group that provides care for all types of cancers - including the rarest forms.
By embracing a crossdisciplinary approach, researchers and physicians develop together cancer-focused basic, translational and clinical research to discover more effective treatments and improve care for patients.
The fellow will join a highly dynamic and motivated team at the hospital in Paris in the Department of Drug Development and Innovation (D3i) at Institut Curie. The D3i led by Pr. Christophe Le Tourneau and certified by Inca (Institut national du cancer) conducts early phase clinical trials and first in human phase I clinical trials. Pr. Christophe Le Tourneau group has been a pioneer in the field of precision medicine with the first published randomized trial worldwide (SHIVA01) (Le Tourneau et al., 2015) that evaluated the efficacy of matched targeted therapy based on a specific treatment algorithm followed by the ongoing SHIVA02 trial (NCT03084757). The group has also demonstrated its ability to lead European projects such as the biobanking BIO-RAIDS study (Scholl et al., 2019) (in the framework of the FP7 programme: RAIDS, http://www.raidsfp7.eu) and PEVOdata project (ERAPERMED2018-078).
The D3i has a dedicated clinical trial unit with 14 beds for early phase clinical trials, allowing the treatment of around 450 patients each year. Clinical specific and multidisciplinary teams dedicated to patient management drive the department, which also includes a scientific coordination unit in charge of the molecular tumor board and the translational studies related to early phase clinical trials and precision medicine studies.
The D3i strongly beneficiates from the outstanding scientific environment of Institut Curie including cutting-edge research programs in immunology, genetics & epigenetics, radiation biology, physics, cell and developmental biology. The fellow will have access to 16 technology platforms recently centralized in the in-house Curie CoreTech (CTT) which covers biological complexity ranging from small molecules to whole organisms. CTT manages access, provides service support and the latest scientific